H.C. Wainwright analyst Yi Chen raised the firm’s price target on Sanara MedTech (SMTI) to $53 from $51 and keeps a Buy rating on the shares following the Q1 report. The firm believes Sanara Surgical segment could continue to drive sales growth as the company increases regional sales managers and territories and grows distribution partners.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMTI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue